197 related articles for article (PubMed ID: 33420961)
1. StarD13 differentially regulates migration and invasion in prostate cancer cells.
Jaafar L; Fakhoury I; Saab S; El-Hajjar L; Abou-Kheir W; El-Sibai M
Hum Cell; 2021 Mar; 34(2):607-623. PubMed ID: 33420961
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of rho GTPases during lung adenocarcinoma migration and invasion reveals a novel role of the tumor suppressor StarD13 in invadopodia regulation.
Al Haddad M; El-Rif R; Hanna S; Jaafar L; Dennaoui R; Abdellatef S; Miskolci V; Cox D; Hodgson L; El-Sibai M
Cell Commun Signal; 2020 Sep; 18(1):144. PubMed ID: 32900380
[TBL] [Abstract][Full Text] [Related]
3. Effect of StarD13 on colorectal cancer proliferation, motility and invasion.
Nasrallah A; Saykali B; Al Dimassi S; Khoury N; Hanna S; El-Sibai M
Oncol Rep; 2014 Jan; 31(1):505-15. PubMed ID: 24253896
[TBL] [Abstract][Full Text] [Related]
4. StarD13 is a tumor suppressor in breast cancer that regulates cell motility and invasion.
Hanna S; Khalil B; Nasrallah A; Saykali BA; Sobh R; Nasser S; El-Sibai M
Int J Oncol; 2014 May; 44(5):1499-511. PubMed ID: 24627003
[TBL] [Abstract][Full Text] [Related]
5. StarD13: a potential star target for tumor therapeutics.
Jaafar L; Chamseddine Z; El-Sibai M
Hum Cell; 2020 Jul; 33(3):437-443. PubMed ID: 32274657
[TBL] [Abstract][Full Text] [Related]
6. StarD13 negatively regulates invadopodia formation and invasion in high-grade serous (HGS) ovarian adenocarcinoma cells by inhibiting Cdc42.
Abdellatef S; Fakhoury I; Haddad MA; Jaafar L; Maalouf H; Hanna S; Khalil B; El Masri Z; Hodgson L; El-Sibai M
Eur J Cell Biol; 2022 Jan; 101(1):151197. PubMed ID: 34958986
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of miR-9-5p suppresses prostate cancer progress by targeting StarD13.
Chen L; Hu W; Li G; Guo Y; Wan Z; Yu J
Cell Mol Biol Lett; 2019; 24():20. PubMed ID: 30899277
[TBL] [Abstract][Full Text] [Related]
8. The regulation of RhoA at focal adhesions by StarD13 is important for astrocytoma cell motility.
Khalil BD; Hanna S; Saykali BA; El-Sitt S; Nasrallah A; Marston D; El-Sabban M; Hahn KM; Symons M; El-Sibai M
Exp Cell Res; 2014 Feb; 321(2):109-22. PubMed ID: 24333506
[TBL] [Abstract][Full Text] [Related]
9. DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma.
El-Sitt S; Khalil BD; Hanna S; El-Sabban M; Fakhreddine N; El-Sibai M
Oncol Rep; 2012 Aug; 28(2):511-8. PubMed ID: 22614672
[TBL] [Abstract][Full Text] [Related]
10. The prostate metastasis suppressor gene NDRG1 differentially regulates cell motility and invasion.
Sharma A; Mendonca J; Ying J; Kim HS; Verdone JE; Zarif JC; Carducci M; Hammers H; Pienta KJ; Kachhap S
Mol Oncol; 2017 Jun; 11(6):655-669. PubMed ID: 28371345
[TBL] [Abstract][Full Text] [Related]
11. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
12. A novel strategy for specifically down-regulating individual Rho GTPase activity in tumor cells.
Wang L; Yang L; Luo Y; Zheng Y
J Biol Chem; 2003 Nov; 278(45):44617-25. PubMed ID: 12939257
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.
Asnaghi L; Vass WC; Quadri R; Day PM; Qian X; Braverman R; Papageorge AG; Lowy DR
Oncogene; 2010 May; 29(19):2760-71. PubMed ID: 20228844
[TBL] [Abstract][Full Text] [Related]
14. Loss of STARD13 contributes to aggressive phenotype transformation and poor prognosis in papillary thyroid carcinoma.
Zeng C; Li H; Liang W; Chen J; Zhang Y; Zhang H; Xiao H; Li Y; Guan H
Endocrine; 2024 Jan; 83(1):127-141. PubMed ID: 37541962
[TBL] [Abstract][Full Text] [Related]
15. GAP-independent functions of DLC1 in metastasis.
Barras D; Widmann C
Cancer Metastasis Rev; 2014 Mar; 33(1):87-100. PubMed ID: 24338004
[TBL] [Abstract][Full Text] [Related]
16. STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
Zheng L; Xiang C; Li X; Guo Q; Gao L; Ni H; Xia Y; Xi T
J Hematol Oncol; 2018 May; 11(1):72. PubMed ID: 29848346
[TBL] [Abstract][Full Text] [Related]
17. FKBP51 regulates cell motility and invasion via RhoA signaling.
Takaoka M; Ito S; Miki Y; Nakanishi A
Cancer Sci; 2017 Mar; 108(3):380-389. PubMed ID: 28032931
[TBL] [Abstract][Full Text] [Related]
18. Role of DLC-1, a tumor suppressor protein with RhoGAP activity, in regulation of the cytoskeleton and cell motility.
Kim TY; Vigil D; Der CJ; Juliano RL
Cancer Metastasis Rev; 2009 Jun; 28(1-2):77-83. PubMed ID: 19221866
[TBL] [Abstract][Full Text] [Related]
19. Lipogenic signalling modulates prostate cancer cell adhesion and migration via modification of Rho GTPases.
De Piano M; Manuelli V; Zadra G; Otte J; Edqvist PD; Pontén F; Nowinski S; Niaouris A; Grigoriadis A; Loda M; Van Hemelrijck M; Wells CM
Oncogene; 2020 Apr; 39(18):3666-3679. PubMed ID: 32139877
[TBL] [Abstract][Full Text] [Related]
20. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice.
Zins K; Lucas T; Reichl P; Abraham D; Aharinejad S
PLoS One; 2013; 8(9):e74924. PubMed ID: 24040362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
